STEMI patients with indication for adjuvant therapy with GPI during pPCI, and who gave informed consent, were randomized, using sealed, opaque envelopes, to either IC or IV bolus (0.25 mg/kg body weight) followed by a 12-hour IV infusion of abciximab (0.125 μg/kg body weight per minute). IC bolus of abciximab was delivered via the PCI guiding catheter directly into the culprit artery, whereas IV bolus was given in a peripheral vein, both after filtering of the drug. The drug of use in our centre is Reo-Pro® manufactured by Eli Lilly, Denmark, who had no involvement, economically or scientifically, in the trial.